Galectin 3 (LGALS3) is over-expressed in ovarian cancer, and so a second protein inhibitor was constructed from the sugar-binding domain of LGALS3 (amino acids 117 to 244; S4C and S4D Fig) attached to the same pFUSE backbone (117-244LGALS3pFUSE) [25]. The gene discussed is LGALS3; the disease is ovarian carcinoma.